Skip to main content
Journal cover image

Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry.

Publication ,  Journal Article
Russo, JJ; Yan, AT; Pocock, SJ; Brieger, D; Owen, R; Sundell, KA; Bagai, A; Granger, CB; Cohen, MG; Yasuda, S; Nicolau, JC; Westermann, D ...
Published in: J Cardiol
April 2022

BACKGROUND: Patterns of dual antiplatelet therapy (DAPT) use beyond 1 year post-myocardial infarction (MI) have not been well studied. METHODS: TIGRIS (NCT01866904) was a prospective, multi-center (369 centers in 24 countries), observational study of patients 1 to 3 years post-MI. We sought to identify the prevalence and determinants of DAPT use ≥1 year post-MI in patients enrolled in TIGRIS. We used multivariable logistic regression to identify determinants of DAPT use at 396 days post-MI (365 days plus a 31day overrun period to account for intended DAPT discontinuation at 1 year). Patients treated with an oral anticoagulant were excluded. RESULTS: Of 7708 patients (median age 67 years, women 25%, ST-elevation MI 50%), 39% and 16% were on DAPT at 396 days and 5 years post-MI, respectively. DAPT use at 396 days post-MI was more prevalent in patients <65 years of age, treated with percutaneous coronary intervention (versus coronary artery bypass grafting or medical therapy), and with multivessel disease or a history of angina. Additional clinical determinants of ischemic and/or bleeding events following MI (diabetes, second prior MI, hypertension, peripheral artery disease, heart failure, smoking, and renal insufficiency) were not independently associated with DAPT use at 396 days. There were geographic variations in the use of DAPT at 396 days (p<0.001), with the lowest use in Europe and the highest in Asia and Australia. CONCLUSION: In a contemporary patient cohort, DAPT use beyond 1 year post MI was prevalent and associated with patient and index event characteristics. There were marked geographical variations in DAPT use beyond 1 year post MI.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Cardiol

DOI

EISSN

1876-4738

Publication Date

April 2022

Volume

79

Issue

4

Start / End Page

522 / 529

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Registries
  • Prospective Studies
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Myocardial Infarction
  • Humans
  • Female
  • Drug Therapy, Combination
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Russo, J. J., Yan, A. T., Pocock, S. J., Brieger, D., Owen, R., Sundell, K. A., … Goodman, S. G. (2022). Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. J Cardiol, 79(4), 522–529. https://doi.org/10.1016/j.jjcc.2021.10.024
Russo, Juan J., Andrew T. Yan, Stuart J. Pocock, David Brieger, Ruth Owen, Karolina Andersson Sundell, Akshay Bagai, et al. “Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry.J Cardiol 79, no. 4 (April 2022): 522–29. https://doi.org/10.1016/j.jjcc.2021.10.024.
Russo JJ, Yan AT, Pocock SJ, Brieger D, Owen R, Sundell KA, et al. Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. J Cardiol. 2022 Apr;79(4):522–9.
Russo, Juan J., et al. “Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry.J Cardiol, vol. 79, no. 4, Apr. 2022, pp. 522–29. Pubmed, doi:10.1016/j.jjcc.2021.10.024.
Russo JJ, Yan AT, Pocock SJ, Brieger D, Owen R, Sundell KA, Bagai A, Granger CB, Cohen MG, Yasuda S, Nicolau JC, Brandrup-Wognsen G, Westermann D, Simon T, Goodman SG. Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registry. J Cardiol. 2022 Apr;79(4):522–529.
Journal cover image

Published In

J Cardiol

DOI

EISSN

1876-4738

Publication Date

April 2022

Volume

79

Issue

4

Start / End Page

522 / 529

Location

Netherlands

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Registries
  • Prospective Studies
  • Platelet Aggregation Inhibitors
  • Percutaneous Coronary Intervention
  • Myocardial Infarction
  • Humans
  • Female
  • Drug Therapy, Combination